Manfred Kindler

456 total citations
28 papers, 381 citations indexed

About

Manfred Kindler is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Manfred Kindler has authored 28 papers receiving a total of 381 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Manfred Kindler's work include Renal cell carcinoma treatment (8 papers), Renal and related cancers (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). Manfred Kindler is often cited by papers focused on Renal cell carcinoma treatment (8 papers), Renal and related cancers (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). Manfred Kindler collaborates with scholars based in Germany, United States and Estonia. Manfred Kindler's co-authors include J Thormann, M. Schlepper, R. Oberneder, Martin Gottwik, Michael Siebels, Michael S. Stahler, Joachim Beck, Nicolas Haseke, Rainer Hofmann and Christian G. Stief and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and Annals of Oncology.

In The Last Decade

Manfred Kindler

28 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Manfred Kindler Germany 12 179 148 131 100 50 28 381
Yasuo Kodera Japan 8 167 0.9× 167 1.1× 120 0.9× 64 0.6× 27 0.5× 14 405
Yuzuru Inoue Japan 12 204 1.1× 158 1.1× 101 0.8× 90 0.9× 47 0.9× 33 440
Masayuki Shitara Japan 16 150 0.8× 231 1.6× 212 1.6× 104 1.0× 31 0.6× 30 464
Peter W. Nagle Netherlands 11 174 1.0× 140 0.9× 88 0.7× 75 0.8× 50 1.0× 16 450
Yukari Ishiguro Japan 12 138 0.8× 148 1.0× 91 0.7× 59 0.6× 47 0.9× 19 364
Johannes Stein Germany 10 171 1.0× 187 1.3× 180 1.4× 74 0.7× 14 0.3× 33 467
J. P. Eder United States 10 148 0.8× 143 1.0× 80 0.6× 77 0.8× 19 0.4× 21 418
Davide Caruso Italy 10 206 1.2× 303 2.0× 43 0.3× 99 1.0× 69 1.4× 24 561
Yida Li China 14 230 1.3× 221 1.5× 252 1.9× 155 1.6× 55 1.1× 58 615
E Mingyan China 11 106 0.6× 211 1.4× 73 0.6× 162 1.6× 60 1.2× 31 420

Countries citing papers authored by Manfred Kindler

Since Specialization
Citations

This map shows the geographic impact of Manfred Kindler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manfred Kindler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manfred Kindler more than expected).

Fields of papers citing papers by Manfred Kindler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manfred Kindler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manfred Kindler. The network helps show where Manfred Kindler may publish in the future.

Co-authorship network of co-authors of Manfred Kindler

This figure shows the co-authorship network connecting the top 25 collaborators of Manfred Kindler. A scholar is included among the top collaborators of Manfred Kindler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manfred Kindler. Manfred Kindler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Quidde, Julia, Manfred Kindler, Andreas Kirsch, et al.. (2017). Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer. Oncology Research and Treatment. 40(1-2). 21–26. 4 indexed citations
2.
Bergmann, Lothar, Christian Doehn, Thomas Steiner, et al.. (2015). Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study. BMC Cancer. 15(1). 303–303. 22 indexed citations
3.
Hofheinz, Ralf‐Dieter, Volker Petersen, Manfred Kindler, et al.. (2014). Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results. BMC Cancer. 14(1). 761–761. 13 indexed citations
4.
5.
Hofheinz, Ralf‐Dieter, Wilfried Grothe, Manfred Kindler, et al.. (2012). Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study.. Journal of Clinical Oncology. 30(4_suppl). 566–566. 5 indexed citations
6.
Bergmann, Lothar, Peter J. Goebell, Manfred Kindler, et al.. (2012). Updated results of a prospective noninterventional study of everolimus after use of 1 VEGFR-TKI.. Journal of Clinical Oncology. 30(15_suppl). e15044–e15044. 1 indexed citations
7.
Pelzer, Uwe, Dirk Arnold, P Reitzig, et al.. (2011). First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group. Cancer Chemotherapy and Pharmacology. 68(5). 1173–1178. 5 indexed citations
8.
Lenz, Matthias, et al.. (2011). Chilaiditi-Syndrom mit subdiaphragmal perforierter Appendizitis. Der Chirurg. 82(9). 828–833. 7 indexed citations
9.
Bergmann, Lars, Manfred Kindler, Thomas Koepke, et al.. (2011). A noninterventional study of everolimus in metastatic renal cell cancer after use of one VEGFR-TKI: Results of a preplanned interim analysis of a prospective study.. Journal of Clinical Oncology. 29(15_suppl). 4552–4552. 4 indexed citations
10.
Siebels, Michael, K. Rohrmann, R. Oberneder, et al.. (2010). A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World Journal of Urology. 29(1). 121–126. 85 indexed citations
11.
12.
Kretzschmar, Albrecht, Salah‐Eddin Al‐Batran, Manfred Kindler, et al.. (2007). Rapid and Sustained Influence of Intravenous Zoledronic Acid on Course of Pain and Analgesics Consumption in Patients with Cancer with Bone Metastases: A Multicenter Open-Label Study Over 1 Year. PubMed. 4(4). 203–210. 14 indexed citations
13.
14.
Bevan, Paul, et al.. (2004). Results of a phase I/II study with monoclonal antibody CG250 in combination with IFN α-2A in metastatic renal cell carcinoma patients. Journal of Clinical Oncology. 22(14_suppl). 4606–4606. 11 indexed citations
15.
Oettle, Helmut, M. Arning, Uwe Pelzer, et al.. (2000). A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Annals of Oncology. 11(10). 1267–1272. 43 indexed citations
16.
Kindler, Manfred, et al.. (1989). Follow-Up of Breast Cancer Patients. Oncology. 46(6). 360–365. 11 indexed citations
17.
Thormann, J, et al.. (1985). Analysis of the efficacy of the new cardiotonic agent TA-064. American Heart Journal. 110(2). 426–438. 13 indexed citations
18.
Kindler, Manfred. (1984). [Lymphedema of the arm after mastectomy--symptom of a recurrence?].. PubMed. 109(7). 479–82. 1 indexed citations
19.
Thormann, J, M. Schlepper, Wilfried Kramer, Martin Gottwik, & Manfred Kindler. (1983). Effects of AR-L 115 BS (Sulmazol), a new cardiotonic agent, in coronary artery disease: Improved ventricular wall motion, increased pump function and abolition of pacing-induced ischemia. Journal of the American College of Cardiology. 2(2). 332–337. 21 indexed citations
20.
Hf, Oettgen & Manfred Kindler. (1959). [Chronic acquired hemolytic anemia. Clinical and immunological studies on 47 cases].. PubMed. 4. 22–76. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yasuo Kodera Breakdown of academic impact, for papers by Yuzuru Inoue Breakdown of academic impact, for papers by Masayuki Shitara Breakdown of academic impact, for papers by Peter W. Nagle Breakdown of academic impact, for papers by Yukari Ishiguro Breakdown of academic impact, for papers by Johannes Stein Breakdown of academic impact, for papers by J. P. Eder Breakdown of academic impact, for papers by Davide Caruso Breakdown of academic impact, for papers by Yida Li Breakdown of academic impact, for papers by E Mingyan
Rankless by CCL
2026